 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp II ARYBU or the Company Nasdaq: ARYBU in connection with the Companys proposed merger with privately-held biopharmaceutical company Cerevel Therapeutics, Inc. Cerevel. Under the terms of the merger agreement, ARYBU will fold into Cerevel and cease to exist, forming one publicly-traded entity with existing Cerevel investors and new PIPE investors. Cerevels management team will continue to lead the combined company, which will trade on the Nasdaq stock exchange under the ticker CERE. 